ActaBiomedicaScientia

e - ISSN - 2348 - 2168
Print ISSN - 2348 - 215X

www.mcmed.us/journal/abs

Research Article

AN INVESTIGATION OF THE BIOCOMPATIBILITY AND IN VITRO EFFICACY OF ANTIBIOTIC-COATED CENTRAL CATHETERS

Dr. Parija Jyothi Prakash*

Assistant Professor, Great Eastern medical College and hospital, Sri kakulam, Andhra Pradesh, India.

ABSTRACT

It is possible that antimicrobial peripherally inserted central catheters, also known as central catheters, will lower the rate of bloodstream infections caused by central lines. This is because piccs, which are also known as central catheters, are inserted into the peripheral arteries. Using an *in vitro* biofilm colonization model, we evaluated the antimicrobial efficacy of a novel gendine-coated (combination of chlorhexidine [chx] and gentian violet [gv]) picc. In this study compares piccs that have been pretreated with minocycline/rifampin (m/r) and cholex. Rabbits were used in the research for this model. For a period of four days, rabbits were implanted with peripherally inserted central catheters (piccs) in their jugular veins. These catheters were either coated with gendine or left uncoated as a control. At the end of the four-day period, a histopathological analysis was performed, A liquid chromatography-mass spectrometry measurement was done at various time points throughout the experiment to determine the concentration of chx and gv in the blood. To test the antimicrobial, the strains of methicillin-resistant *staphylococcus aureus*, vancomycin-resistant enterococci, *Pseudomonas aeruginosa*, *Escherichia coli*, *Acinetobacterbaumannii*, *Enterobacter cloacae*, *candida albicans*, and *candida glabrata* were isolated from clinical samples. In rabbits, gendine-coated piccs demonstrated a significantly lower rate of thrombosis and inflammation following simulated intravascular indwellings of 24 hours and 1 week compared to uncoated controls. This was the case when comparing the two groups of rabbits. During the entirety of the research project, not a single instance of gv was discovered in any of the blood samples; on the other hand, chx was discovered in extremely low concentrations. From 24 hours to 1 week, all pathogens were completely prevented from adhering to the gendine-coated piccs (p 0,001), whereas it was not prevented on the m/r-treated, chx-treated, or control piccs. Piccs that had been coated with gentine were found to be very effective at preventing the formation of biofilm by multidrug-resistant bacterial and fungal pathogens. This was demonstrated by the fact that no biofilm was found on the piccs. Piccs with a gendine coating were found to be biocompatible when used within the intravascular environment. In addition, from pharmacokinetic testing, it was determined that chx and gv were well within safe limits during acute systemic exposure from the gendine-coated catheters. This was determined by the fact that the acute exposures were measured in milligrams per kilogram of body weight. This was proven by the fact that the levels were located well within the acceptable ranges for safety.

Keywords:- Anti-biotics, catheters, blood stream infections, gendine-coated catheters

Access this article online		
Home Page: **www.mcmed.us/journal/abs**		**Quick Response code**
Received:22.07.2014	**Revised**:12.08.2014	**Accepted**:28.08.2014

INTRODUCTION

The use of peripherally inserted central catheters (piccs), such as the indwelling central line, is key to improving the quality of vascular care among hospitalized and critically ill patients has recently been

Corresponding Author**: Dr. Parija Jyothi Prakash** Email: **drvrvkk@gmail.com**

increasing. This is because piccs allow for prolonged vascular access, which is essential for the delivery of chemotherapy, dialysis, nutrition, and a wide variety of other diagnostics and medications [1]. In spite of the fact that they have the potential to save lives, peripherally inserted central catheters, also known as piccs, have been associated with bloodstream infections known as central line-associated bloodstream infections, or clabsis [2–4]. These infections can cause hospital stays to last longer, which in turn leads to an increase in both costs and mortality rates [2, 5]. Patients who are in critical condition have a rate of 2.1 infections related to piccs for every 1,000 catheter days (4). According to the findings of a meta-analysis that was carried out not too long ago on clabsis associated with piccs, it was discovered that picc-associated clabsis occur in hospitalised patient settings at the same frequency as those associated with central venous catheters (cvcs). This research was carried out on clabsis associated with piccs [6]. It was recently estimated by the centers for disease control and prevention (cdc) that there were 18,000 clabsis that took place 23,000 cases of clabsi occurred in patients outside of intensive care units (icus), according to the CDC. Additionally, 2009 in the United Kingdom was estimated to have recorded 18000 cases of clabsis in intensive care units. [7]. In addition, there were 37,000 cases of clabsi that were reported among patients in 2008 who were receiving hemodialysis treatment in an outpatient setting [7]. Only among cancer patients are there at least 400,000 new cases of clabsi reported each year [8] , and estimates place the total annual cost anywhere from $296 million to $2.3 billion [9,–11].

Recently revised guidelines [3] published by the centers for disease control and prevention acknowledge the important role catheters with antimicrobial coatings have in helping to prevent device-associated infections during intensive care. In response to this acknowledgement, the cdc upgraded their recommendations for the use of these catheters to the highest level possible (1a). Using catheters coated with minocycline and rifampin (m/r), it has been demonstrated that catheter-related bloodstream infections (clabsi) are less likely to occur. Chryxidine and silver sulfadiazine (chx/ss) antimicrobial catheters were shown to reduce the rate of catheter-related bloodstream infections in a clinical trial that was conducted nearly two decades ago [12]. The trial was randomised and prospective, and it was conducted in the united states (clabsi). On the other hand, in a more recent and more extensive randomised prospective trial, these catheters were unable Clabsi rates should be significantly reduced [13, 14]. It has not been studied empirically to determine whether it decreases clabsi rates. Recent advancements have included a picc that is treated only with chx [15]. A number of *in vitro* studies have also found that m/r- and chx-treated piccs, whether commercially available or not, may not effectively deter gram-negative bacteria such as pseudomonas aeruginosa and fungi such as candida species from colonizing catheters. This was found to be the case despite the fact that these piccs are marketed to reduce the risk of catheter colonisation caused by these pathogens. This is the inference that one can make after taking into account the findings of the studies [16]. As a consequence of this, there is an ongoing need for a picc that is either impregnated or coated with an antimicrobial agent and Gram-negative bacteria and fungi are susceptible to its effects.

In order to meet this demand, we came up with a brand new picc that was coated with gendine, which is a combination of gentian violet and chlorhexidine. In a well-established model of bio-film colonisation, A comparison was made between its antimicrobial effectiveness and durability against pathogens isolated from our hospital that are highly pathogenic and resistant [10]. In addition, we compared it with commercially available piccs that are m/r- and chx-treated. It is important to consider the biofilm colonisation model since microbial adherence to indwelling catheter surfaces leads to formation of a biofilm over a complex process that includes primary adherence, cell-to-cell interactions, colony formation, and maturation of the biofilm [17]. Polysaccharides, proteins, and nucleic acids constitute the majority of polymeric materials found in biofilms, which are extremely complex communities. Biofilms can be found in a variety of environments, including marine, freshwater, and soil [18]. These biofilms have the ability to hold onto nutrients for their constituent cells while also shielding those cells Antimicrobial agents and host immune responses [19]. Biofilms are clinically significant because they are responsible for more than eighty percent of microbial infections in the body. There is a correlation between the formation of biofilms and as many as sixty percent of all microbial infections [20]; biofilms are clinically significant because there is a correlation between the formation of biofilms and as many as sixty percent of all microbial infections [21]. A histopathological examination was performed and circulating antiseptic levels in the blood were analyzed using liquid chromatography-mass spectrometry to test the acute biocompatibility of the gendine-coated catheter in vivo in a rabbit intravascular model. This was done in order to determine whether or not the catheter would be safe to use in a live animal. This was done in order to establish whether or not the catheter could be used without causing any harm.

MATERIALS AND METHODS

A step-by-step process was used to apply the coating of gendine to the catheter.

Following extrusion, gendine-coated polyurethane intravenous catheters (piccs) were produced by putting polyurethane piccs through a specialised sequential treatment process. This was done in order to create the catheters. As a direct consequence of this, gendine was incorporated not only into the walls of the catheter but also into its luminal and external surfaces. Gendine was produced by combining gentian violet, which was available for purchase from sigma-aldrich in st. Louis, missouri, and chlorhexidine (sigma-aldrich). In the research being conducted, both the controls and the comparators were in the form of polyurethane piccs that were readily available for purchase. At the radiation facility of the md anderson cancer center, piccs that were either uncoated or coated with gendine were gamma-sterilized in order to remove any potentially harmful bacteria. Piccs that had been sterilised with m/r or chx prior to packaging were kept in a sterile environment.

Biofilm colonisation acts as a testing ground for determining the Genentech-coated catheter antimicrobial efficiency at baseline. This is done by exposing the catheters to the biofilm.

The following catheters were tested using a biofilm colonisation model to determine whether or not they had A comparison of catheters treated with M/R, Chx, and Gendine for their ability to prevent biofilm formation [16, 22]. In a study performed on piccs uncoated, m/r-treated segments, chx-treated segments, and gendine-coated segments, researchers assessed their ability to inhibit the formation of biofilm by methicillin-resistant staphylococci (mrsa) strain mdacc4798 and vancomycin-resistant enterococci strain mdacc3238. Aeruginosa strain mdacc4689, and Escherichia these isolated strains originated from patients who were infected at our medical facility and were collected from those patients. At the beginning of the procedure, there was a sterile 24-well tissue culture plate containing one milliliter of human donor plasma, along with triplicate picc segments. This was done so that the formation and binding of blood proteins could be improved. After that, the plates were heated to 37 degrees celsius and left there for a full day. We then removed the plasma from the incubation and replaced it with mueller-hinton broth containing 5.0 x 105 cells from diverse species of organisms. This continued until the completion of the incubation process. After that, this mixture was allowed to continue to incubate for another twenty-four hours. After the incubation period was complete, the microbial inoculum was discarded, and the segments were washed by shaking them for thirty minutes in one milliliter of sterile saline that contained 9.9 percent sodium chloride. Following the removal of the segments using sterile sticks, they were suspended in 5 milliliters of saline solution containing a concentration of 0.9% and subjected to sonication for a period of 15 minutes. During the process of sonication, a five-ml wash in dey/engley (d/e) neutralizing broth was also used to test the catheter segments in an effort to stop any antiseptic activity that may have been left behind. This was done in an effort to prevent any cross-contamination from occurring [23, 24]. After sonication, each sample was given a 5-second spin in a vortex. Next, 100 l of liquid from each segment was serially diluted and spread onto a plate containing trypticase soy agar with 5% sheep blood. Finally, the plate was incubated at 37 degrees celsius for 24 hours. This was done in order to facilitate the performance of a for yeast, we used sabouraud dextrose agar to culture the cultures. After that, the plates were put in an oven at 37 degrees celsius for twenty-four hours while they were turned upside down, and then the growth of the colonies was measured. Five colonies were required as the bare minimum for any detection to be made. The experiments were carried out a total of three times, which resulted in a total of six distinct segments.

The durability of the protection against biofilm colonisation offered by the gendine coating that is applied to catheters

Following an incubation period of one week in serum, We tested the length of time it takes for MRSA, VRE, and P to inhibit the formation of biofilm on uncoated control, m/r-treated, and chx-treated gendine-coated picc segments. NOSA, |*E. Coli*, *A. Baumannii*, *E. Cloacae*, *K. Pneumoniae*, *C. Albicans*. To simulate the release of biological antimicrobial agents from an indwelling picc, 12 segments of each picc were soaked in serum for ten milliliters and incubated at 37 degrees Celsius for seven days. Simulating the release of a PICC was done in this way. The serum samples were removed after a week, then put through a series of tests to determine the degree to which the antimicrobial activity of the samples was still present after being subjected to a biofilm colonization model [16, 22].

Examination of the product's viability in living organisms (*in vivo*)

The facility at the md anderson cancer center that is dedicated to the conduct of research involving animals was utilised for the study. As was discussed in the previous section, the in vivo model consisted of a living rabbit [25]. New zealand women (female) white rabbits ranging in weight from 2.5 to 3.5 kg were used in the experiment after being acclimatised to the environment for a week. The hygienic procedures of surgery were carried out in a room designated specifically for that purpose, known as an operating room. After the rabbits were initially put under general anaesthesia with isoflurane at a concentration of 5 percent, they were subsequently intubated and given isoflurane for their local anaesthesia (0.8 to 1.5 percent).

After bluntly dissecting the subcutaneous tissue to expose the jugular vein in each rabbit and making Rabbits are shaved at the right jugular groove using a small incision, gamma-sterilized 5-french picc catheters were then inserted through the incision. The catheters were approximately 15 centimetres (about 6 inches) long. After isolating the jugular vein, a complete wrapping of it was accomplished with a silk suture of the 3-0 size. An incision was made in the vein, then the catheter was guided toward the heart by inserting it in the jugular vein after the vein had been cut. The incision was stitched back together with the assistance of some surgical glue. First, surgical glue was used to secure the catheter in place at the site of the venous incision. Next, the catheter was tacked to the muscle to further ensure that it would not shift out of place. Using a trocar, the remaining portion of the catheter was threaded through the skin and tunnelled subcutaneously to the dorsal scapular region. After that, it was affixed to the muscle tissue that lay beneath the skin, exteriorized via a Sutured under the skin after ligating and stapling the incision.

Both herds of rabbits were kept apart from one another for their own safety (a and b). Piccs coated with gendine were inserted into the jugular veins of three rabbits in group a, while Two rabbits were implanted with uncoated control piccs in group b. The results of this study are presented below. The exact same procedure was carried out on both groups. We took the temperatures of the rabbits, as well as measurements of their body weight loss, the amount of food and water that they consumed, as well as their overall intake. In order to obtain control samples of blood, the ear vein was punctured 0 hours before the experiment began. This was done before the catheters were actually inserted into the patients. Following the insertion of the catheters, At 2, 24, 72, and 96 hours, blood samples were drawn from the ear veins later respectively. After being centrifuged to separate the plasma from the blood samples, the samples were stored at a temperature of -80 degrees celsius in order to determine their chlorhexidine and gentian violet concentrations, they were analyzed by liquid chromatography-mass spectrometry. They were then presented with the results.

After they had passed away, rabbits were dissected and histopathology was performed on them

After the rabbits were put to death by giving them an overdose of euthanasia medication intravenously, complete necropsies were performed on their bodies to determine what had caused their deaths. When collecting the tissue samples, a sterile surgical technique was utilised at all times to ensure patient safety. It was done to collect A tissue sample from the dorsal scapular area, derived from the jugular vein and the subcutaneous tunnel then it was done to place those tissues in formalin and glutaraldehyde at a concentration of five percent. Each tissue sample that was sent in was An evaluation of the histological findings of paraffin processed tissues, sections, and staining with hematoxylin and eosin. Additionally, each tissue sample had three cross-sections that were analysed for toxicity and inflammatory infiltrate. When a pathologist examined the sections of tissue that were taken from the patient, they did so without being aware of which treatment group the patient was in. Blinding was used for both the person who collected the tissue and blood samples as well as the pathologist, so neither of them knew which kind of catheter was used in each rabbit. This ensured that the results of the study would be accurate. In addition to that, the rabbits were made blind. The extent of the inflammatory response was evaluated based on the number of inflammatory cells that were counted, which served as the basis for this evaluation.

Using liquid chromatography and mass spectrometry, an investigation of chlorhexidine and gentian violet was carried out

The analytical technique known as liquid chromatography-tandem mass spectrometry (lc-ms/ms) was utilised in order to recognise and quantify both chlorhexidine (chx) and gentian violet (gv). This method was carried out with the assistance of an ultraperformance liquid chromatography apparatus - a waters acquityultraperformance liquid chromatography - coupled to a waters xevotq-s triple quadrupole mass spectrometer that was situated in milford, massachusetts and featured a temperature-controlled oven. The temperature-controlled oven was located in phenomenexkinetex phenyl-hexyl column was the analytical column that was used to chromatographically separate the compounds. It had a particle size of 2.6 microns and dimensions of Torrance, California, 2.1 by 100 millimeters. We employed a linear gradient consisting of water (a) 0.1 percent formic acid and acetonitrile (b) 0.1 percent formic acid. In 4.75 minutes, the gradient went from being five percent b to being ninety-five percent b. Through the experiment, the flow rate and temperature were kept at 0.300 mL per minute and 60 degrees Celsius, respectively. Ten minutes' worth of time was required in order to finish the analysis in its entirety. The retention time for chx was 3.29 0.1 minutes, while the retention time for gv was 4.53 0.1 minutes. When it came to the detection and quantification of chx and gv, the precise mass transitions that were used were 253.2 to 170.0 and 372.2 to 356.4, respectively. The protein in the plasma samples could be precipitated by adding ice-cold acetonitrile to the plasma in a ratio of 1:1 volume-to-volume. This allowed the protein to be separated from the plasma. The plasma samples went through this process in order to analyse them. The chx

and gv recovery rates were both significantly higher than ninety percent. Following this step, a portion of the sample that had previously been cleaned of protein was transferred into an lc sample vial so that it could be analysed using lc-ms/ms. High-performance liquid chromatography (hplc) was conducted on rabbit blood samples with each analytical scientist blinded to the catheter type.

Statistical analysis techniques and procedures

In order to make a comparison of the viable cfu that were recovered from biofilm colonisation model tests, the kruskal-wallis test was first applied to each organism. The purpose of this was to determine whether or not there was a significant difference between the organisms Awilcoxon rank sum test was used to assess the significance of a significant result in the test to those found on the other types of catheters, including chx-treated catheters, m/r-treated catheters, and uncoated control catheters. The levels of the post hoc pairwise comparisons were adjusted using holm's sequential bonferroni method in order to lower the probability of making a type i error. A two-way nonparametric analysis of variance was utilised in order to make comparisons of colony forming units (cfu) between the different kinds of catheters (ANOVA). From week 0 through week 1, this was done so that an evaluation could be made regarding how stable the prolonged biofilm inhibition was. All of the tests, with the exception of the specific pairwise comparisons that we carried out, were divided into two parts, and a significance level of 0.05 was applied to each one. In every one of the statistical analyses, the version 9.3 of SAS was the software that was utilised (SAS institute, INC., CARY, NC).

Results

In this study, the pharmacokinetics of chlorhexidine and gentian violet were investigated using the LC-MS technique

Plasma collected from rabbits with gendine-coated catheters as well as plasma spiked with gentiana violet and chlorhexidine standards both produced results that showed the presence of chlorhexidine and gentian violet without the presence of any interfering peaks. This was the case regardless of whether the plasma was spiked with the standards or collected from rabbits. In the range of 0.05 ng/ml to 2.5 ng/ml, the linear correlation curve was observed and the correlation coefficients were calculated for chlorhexidine and gentian violet, respectively, were 0.9937 and 0.9995. At their respective concentrations, 0.05 ng/ml was found to be the level below which chlorhexidine and gentian violet could be distinguished from background noise. After two hours, the mean concentration of chx was 0.91 ng/ml; after 24 hours, it was 1.08 ng/ml; after 72 hours, it was 0.41 ng/ml; and after two days, it was 0.29 ng/ml. At two hours, it was 0.91 ng/ml; at 24 hours, it was 1.08 ng/ml; at 72 hours, it was 0.41 ng/ml (at 96 h). After conducting the necessary tests, the researchers found that none of the plasma samples contained any detectable levels of the gene gv (table 1).

TABLE 1: Chlorhexidine and gentian violet concentrations in plasma as assessed by liquid chromatography/mass spectrometry

Rabbit group[a]	**CONCN (ng/ml) at time (h):**									
	0		**2**		**24**		**72**		**96**	
	CHX	**GV**	**CHX**	**GV**	**CHX**	**GV**	**CHX**	**GV**	**CHX**	**GV**
Control rabbits										
#1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
#2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Mean ± SD	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
GEN-rabbits										
#1	0.00	0.00	0.92	0.00	0.60	0.00	0.40	0.00	0.32	0.00
#2	0.00	0.00	0.92	0.00	2.28	0.00	0.52	0.00	0.40	0.00
#3	0.00	0.00	0.88	0.00	0.36	0.00	0.32	0.00	0.16	0.00
Mean ± SD	0.00	0.00	0.91 ± 0.02	0.00	1.08 ± 1.05	0.00	0.41 ± 0.10	0.00	0.29 ± 0.12	0.00

[a]the rabbits that were used as the control group had catheters inserted into their jugular veins that did not have any kind of coating on them. Two rabbits were utilized for the purpose of functioning as the control group. In order to carry out the experiment on the GEN-rabbits, catheters covered in gendine were inserted into the rabbits' jugular veins. The standard procedure called for there to be three rabbits in the experimental group. In order to get ready for inserting the catheters at the beginning of the experiment (0 h), blood samples were taken at the beginning of the experiment. In their respective tests, chlorhexidine (CHX) and gentian violet (GV) each had a detection limit of 0.5 pg/ml as their lowest possible concentration.

DISCUSSION

According to the findings of our research, gendine-coated catheters Coated catheters have been found to reduce the formation of biofilms and the subsequent colonization by multi-resistant Gram-positive and Gram-negative bacteria and fungi significantly more than uncoated catheters. In addition to these microorganisms, *P. aeruginosa*, *E. coli*, *A. baumannii*, *E. cloacae*, *C. albicans*, and *C. glabrata* (P 0.0001). Furthermore, the gendine-coated catheters provided a significantly higher antibiofilm activity and proved to be significantly better than the M/R and CHX-treated catheters that are commercially available against the majority of the pathogens that were examined. These findings were based on a comparison of the catheters' antibiofilm activities and levels of effectiveness. After a week of immersion in serum, Genedine-coated catheters prevented the formation of biofilm significantly better than those treated with traditional M/R and CHX colonisation by a variety of nosocomial pathogens. This was determined by testing the catheters. This was the case when examining the similarities and differences between the three varieties of treated catheters.

In large prospective randomised trials [26, 28, 29] M/R-treated catheters were observed to provide prolonged antimicrobial activity in vitro [26], had excellent activity against multidrug-resistant staphylococci [27], and completely prevented CLABSIs caused by staphylococci in the pilot study [28]; however, M/R-treated catheters were not completely effective in preventing CLABSIs caused by Gram-negative bacteria, such as Klebsiellapneumoniae, Entero. Between 1986 and 1999, 14% to 19% of all CLABSI cases in the United States were caused by Gram-negative bacteria. Between 2004 and 2008, 28% of all CLABSI cases in the United States were caused by Gram-negative bacteria. There was an increase of 19 percent between the years of 1986 and 1999 in the number of CLABSI cases. [32]. The mortality rate associated with health care-associated candidemia is reported to range between 38 and 49 percent. Candida species account for approximately 15 percent of all CLABSIs. This information comes from various sources [33]. Therefore, our cutting-edge gendine-coated catheter has the potential to be helpful in preventing catheter-related infections caused by Gram-negative bacterial CLABSIs along with Gram-positive bacterial and fungal catheter-related infections. This is because gendine is known to inhibit the growth of Gram-negative bacteria.

Gendine is constructed out of its two constituent chemicals, which are gentian violet and chlorhexidine. The gentian violet dye is a triphenylmethane compound that has properties that are effective against bacteria, fungi, and helminths. Since a significant number of years ago, gentian violet has been used all over the world Patients suffering from oropharyngeal candidiasis can use it as an oral rinse. Skin lesions around the neonatal oral cavity are the most common reason for using this method. A wide variety of medical applications have been accomplished with the help of these applications. It has been demonstrated that the cationic polybiguanidechlorhexidine possesses antimicrobial activity. In addition to this, it has been implemented in a wide variety of different medical contexts. As a hand scrub and for disinfecting surgical sites on the skin, a solution of chlorhexidine and alcohol is used [37, 38]. [37, 38]. In addition, studies have shown that the use of chlorhexidine in the treatment of infections of the umbilical cord in newborns is effective [39–41]. In addition to this, chlorhexidine has been infused into latex gloves through a process known as the impregnating process [42]. Chlorhexidine is one of the two antimicrobial components that are found in gendine. It is the one that makes the outer membranes of pathogens more permeable, which in turn causes the contents of their cells to leak out. Gendine is used to treat a variety of bacterial infections [43]. One of the mechanisms by which gentian violet inhibits DNA replication is that it induces cell penetration and DNA binding. The formation of hydroxyl and perhydroxy radicals is the mechanism that enables this to take place [44, 45]. Despite the fact that chlorhexidine and gentian violet each have their own unique mechanisms of action, our hypothesis is that In combination with gentian violet, chlorhexidine leads to an increase in permeability.

A new antiseptic combination, gendine, that is not commonly used for treating systemic infections, is expected to prove more effective than current catheter treatments and may lead to a decrease in the likelihood of antibiotic-resistant pathogens evolving. A systemic infection cannot be treated with gendine. In addition, there have been reports in recent times of pathogens that are becoming increasingly resistant to chlorhexidineon its own. This is something that is happening more and more frequently. There have been reports of chlorhexidine resistance in Chlorhexidine is resistant to Gram-negative bacteria like P. aeruginosa, A. baumannii, K. pneumoniae, and E. coli [46–48], as well as MRSA isolates have been found to be resistant to chlorhexidine. In addition, there have been reports of chlorhexidine resistance in Gram-positive bacteria such as K. pneumoniae [48]. In addition, recent reports have indicated that clinical isolates of A. baumannii have demonstrated increases in the minimum inhibitory concentrations (MICs) that chlorhexidine requires in order to beeffective against the bacteria [49]. In this case, the CHX PICC, which contains only chlorhexidine, not only does not effectively fight pathogens with resistance to chlorhexidine, but also poses a threat to causing infection in other parts of the body but it also helps to

contribute to the development of pathogens that are resistant to chlorhexidine. In point of fact, the findings of this study shed light on the restrictions placed on the effectiveness of the CHX PICC in combating multidrug-resistant Gram-negative and fungal organisms. [Citation needed] [Citation needed] In contrast, the gendine-coated PICC not only had The gendine-coated catheter has significant antimicrobial efficacy, but also a low risk of developing chlorhexidine-resistant bacteria and fungus as a result of being used in conjunction with antiseptic treatment.

Our rabbit model was found to have very low levels of chlorhexidine pharmacokinetics, with concentrations between 0.29 and 1.1 ng/ml over a four-day period. These results were obtained after administering the drug to the rabbits over the course of four days. These levels of chlorhexidine were a considerable amount lower than the level that earlier research had shown to be safely tolerated by the body. After an umbilical cord disinfection treatment with chlorhexidine at a concentration of one percent for a period of nine days, the 23 newborns were tested and 32 ng/ml of chlorhexidine was detected in their blood. In this case, the treatment was administered to the 50 infants. The results of a more recent study revealed that our children exposed to chlorhexidine had chlorhexidine levels of up to 4.5ng/ml in 23 of their blood samples, and 17ng/ml in 15 of them. By analyzing the chlorhexidine levels in the children's blood [51] it was determined that the children had been exposed to chlorhexidine. Chlorhexidine was detected in the blood of 34 out of 96 patients after they were washed with 0.2 percent chlorhexidine solutions after vaginal washing. Levels varied between 10ng/ml and 83ng/ml in the blood samples. This was in response to the fact that the levels of chlorhexidine were found to be present in the vaginal washing solution. These levels ranged anywhere from ten to eighty-three ng/ml [52]. In another study, researchers found that ten out of twenty infants who had received chlorhexidine antiseptics at a concentration of 2 percent just prior to the insertion of a PICC line [53] had detectable levels of chlorhexidine in their serum, ranging from 1.6 to 206 ng/ml. This was the case even though the infants had received the chlorhexidine antiseptics just prior to the insertion of the PICC line. Chronic exposure levels to chlorhexidine from the gendine-coated catheter will likely be equivalent to those of catheters in general. Blood samples from this patient did not contain any gentian violet.

The antimicrobial testing that was done for our current gendine-coated catheter study was performed using a quantitative biofilm colonisation model. This is one of the most significant differences between our previousgendine-coated catheter study [22] and the study that we are currently conducting. Our team has reported in the past [22–24, 34] that address the design of devices treated with gendine including endotracheal tubes, CVCs, urinary catheters, and gloves made of various polymers. A wide variety of bacteria and fungi were shown to be effectively inhibited by the gendine coating of these devices [22-24, 34]. Moreover, an infusion of gendine into rabbit urinary catheters significantly reduced urinary tract infections (54) that was put through an E. coli test. This was the case even though the rabbit was exposed to the bacteria.

Although there is a slight difference in inflammatory changes between the uncoated control catheters and the gendine-coated catheters, based on the variety and number of samples that were examined, there does not appear to be any treatment-related effect. Although the thrombotic and inflammatory changes observed in the untreated control catheters tended to be worse when compared to that observed in the gendine-coated catheters, despite the fact that there were overlapping variations. This was the case despite the fact that there were overlapping variations. It has been demonstrated that gentian violet has the ability to inhibit NADPH oxidases in mammalian cells, which ultimately leads to an inhibition of NF-kB and anti-inflammatory activity [55]. It's possible that this is one of the factors that leads to the phenomenon.

The presence of gentian violet was investigated using blood samples taken from rabbits, but no detectable levels of the pigment were found in the rabbits' blood. Based on these findings, it appears that very little to no gentian violet is absorbed or accumulated in the blood. It was reported that hundreds of thousands of people in South America [55] used gentian violet as a direct additive to their blood at concentrations of 0.6 mM (>200,000 ng/ml) in order to prevent the transmission of Chagas disease [45, 56]. This was accomplished without any major adverse effects, and the patient tissues were only stained in a reversible manner. In a clinical trial that involved seventy elderly patients and looked at the topical treatment of full- and partial-thickness wounds with one percent gentian violet, more than ninety percent of the wounds were completely healed. There were no adverse effects linked to the gentian violet, and the wounds completely healed in more than ninetieth of the cases [57]. A recent study reports the clinical use of gentian violet at concentrations of less than 0.1 percent in the treatment of complex dermatology patients and in the treatment of skin cancer [55], and this was found to be safe and effective.

The conclusions that can be drawn from this research are hampered by a number of factors. To begin, the microbiologist who took part in this study and was responsible for conducting the biofilm colonization experiment on catheters did not have their eyes covered during the process. Second, the primary objective of the

in the study, chlorhexidine and gentian violet were tested for their acute toxicity. This was the primary reason for conducting the research. In the future, we are going to investigate how chronic toxicity affects the prolonged implantation of catheters and see what effects it has. Specifically, we are going to look into the effects that it has.

CONCLUSIONS

PICCs that had been treated with gendine M/R and CHX significantly outperformed PICCs that were commercially available in terms of preventing a wide variety of highly pathogenic Gram-positive and Gram-negative bacteria and fungi from forming biofilm on the PICCs. This was the case in terms of preventing the formation of biofilm. The fact that both of these treatments were already available on the market did not change the outcome of this situation. Chlorhexidine and gentian violet acute exposures from gendine-coated catheters were either negligible in the case of gentian violet or well within safe levels in the case of chlorhexidine, based on the results of pharmacokinetic testing. During testing for gentian violet, it was found that gendine-coated catheters caused acute systemic exposure. In the case of gentian violet, the testing revealed that the gendine coating was the source of the acute systemic exposures. In addition to this, it was found that gendine-coated catheters are biocompatible and have a good safety profile when they are utilised in an intravascular setting. In addition, histopathologic examinations carried out on rabbits demonstrated that tissues that were treated with gendine-coated catheters exhibited milder implant responses than those that were treated with catheters that did not contain any antimicrobial agents. In the not too distant future, it will be possible to make comparisons that are statistically significant by using animal studies that involve larger populations.

REFERENCES

1. Raad I, Hanna H, Maki D. 2007. Intravascular catheter-related infections: advances in diagnosis, prevention, and management. Lancet Infect Dis 7:645–657.
2. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, Raad II, Rijnders BJ, Sherertz RJ, Warren DK. 2009. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 49:1–45.
3. O'Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, Lipsett PA, Masur H, Mermel LA, Pearson ML, Raad II, Randolph AG, Rupp ME, Saint S, Healthcare Infection Control Practices Advisory Committee (HICPAC). 2011. Summary of recommendations: guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 52:1087–1099.
4. Safdar N, Maki DG. 2005. Risk of catheter-related bloodstream infection with peripherally inserted central venous catheters used in hospitalized patients. Chest 128:489–495.
5. Pronovost P, Needham D, Berenholtz S, Sinopoli D, Chu H, Cosgrove S, Sexton B, Hyzy R, Welsh R, Roth G, Bander J, Kepros J, Goeschel C. 2006. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med 355:2725–2732.
6. Chopra V, O'Horo JC, Rogers MA, Maki DG, Safdar N. 2013. The risk of bloodstream infection associated with peripherally inserted central catheters compared with central venous catheters in adults: a systematic review and meta-analysis. Infect Control HospEpidemiol 34:908–918.
7. Centers for Disease Control and Prevention. 2011. Vital signs: central line-associated blood stream infections–United States, 2001, 2008, and 2009. MMWR Morb Mortal Wkly Rep 60:243–248.
8. Jamal MA, Rosenblatt JS, Hachem RY, Ying J, Pravinkumar E, Nates JL, Chaftari AM, Raad II. 2014. Prevention of biofilm colonization by Gram-negative bacteria on minocycline-rifampin-impregnated catheters sequentially coated with chlorhexidine. Antimicrob Agents Chemother 58:1179–1182.
9. Mermel LA. 2000. Prevention of intravascular catheter-related infections. Ann Intern Med 132:391–402.
10. O'Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, Lipsett PA, Masur H, Mermel LA, Pearson ML, Raad II, Randolph AG, Rupp ME, Saint S, Healthcare Infection Control Practices Advisory Committee (HICPAC) . 2011. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 52:e162–e193.
11. Yousif A, Jamal MA, Raad I. 2015. Biofilm-based central line-associated bloodstream infections. AdvExp Med Biol 830:157–179.
12. Maki DG, Stolz SM, Wheeler S, Mermel LA. 1997. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter. A randomized, controlled trial. Ann Intern Med 127:257–266.

13. Brun-Buisson C, Doyon F, Sollet JP, Cochard JF, Cohen Y, Nitenberg G. 2004. Prevention of intravascular catheter-related infection with newer chlorhexidine-silver sulfadiazine-coated catheters: a randomized controlled trial. Intensive Care Med 30:837–843.
14. Rupp ME, Lisco SJ, Lipsett PA, Perl TM, Keating K, Civetta JM, Mermel LA, Lee D, Dellinger EP, Donahoe M, Giles D, Pfaller MA, Maki DG, Sherertz R. 2005. Effect of a second-generation venous catheter impregnated with chlorhexidine and silver sulfadiazine on central catheter-related infections: a randomized, controlled trial. Ann Intern Med 143:570–580.
15. Allan ND, Giare-Patel K, Olson ME. 2012. An *in vivo* rabbit model for the evaluation of antimicrobial peripherally inserted central catheter to reduce microbial migration and colonization as compared to an uncoated PICC. J Biomed Biotechnol 2012:921617.
16. Raad I, Mohamed JA, Reitzel RA, Jiang Y, Raad S, Al Shuaibi M, Chaftari AM, Hachem RY. 2012. Improved antibiotic-impregnated catheters with extended-spectrum activity against resistant bacteria and fungi. Antimicrob Agents Chemother 56:935–941.
17. Donlan RM. 2002. Biofilms: microbial life on surfaces. Emerg Infect Dis 8:881–890.
18. Sutherland I. 2001. Biofilm exopolysaccharides: a strong and sticky framework. Microbiology 147:3–9.
19. DeQueiroz GA, Day DF. 2007. Antimicrobial activity and effectiveness of a combination of sodium hypochlorite and hydrogen peroxide in killing and removing Pseudomonas aeruginosa biofilms from surfaces. J ApplMicrobiol 103:794–802.
20. Costerton JW, Stewart PS, Greenberg EP. 1999. Bacterial biofilms: a common cause of persistent infections. Science 284:1318–1322.
21. Lewis K. 2001. Riddle of biofilm resistance. Antimicrob Agents Chemother 45:999–1007.
22. Boktour M, Hanna H, Ansari S, Bahna B, Hachem R, Tarrand J, Rolston K, Safdar A, Raad I. 2006. Central venous catheter and Stenotrophomonasmaltophilia bacteremia in cancer patients. Cancer 106:1967–1973.
23. Raad II, Mohamed JA, Reitzel RA, Jiang Y, Dvorak TL, Ghannoum MA, Hachem RY, Chaftari AM. 2011. The prevention of biofilm colonization by multidrug-resistant pathogens that cause ventilator-associated pneumonia with antimicrobial-coated endotracheal tubes. Biomaterials 32:2689–2694.
24. Reitzel R, Rosenblatt J, Jiang Y, Hachem R, Raad I. 2014. Disposable gendine antimicrobial gloves for preventing transmission of pathogens in health care settings. Am J Infect Control 42:55–59.
25. Hachem RY, Wright KC, Zermeno A, Bodey GP, Raad II. 2003. Evaluation of the silver iontophoretic catheter in an animal model. Biomaterials 24:3619–3622.
26. Darouiche RO, Berger DH, Khardori N, Robertson CS, Wall MJ Jr, Metzler MH, Shah S, Mansouri MD, Cerra-Stewart C, Versalovic J, Reardon MJ, Raad II. 2005. Comparison of antimicrobial impregnation with tunneling of long-term central venous catheters: a randomized controlled trial. Ann Surg 242:193–200.
27. Raad I, Reitzel R, Jiang Y, Chemaly RF, Dvorak T, Hachem R. 2008. Anti-adherence activity and antimicrobial durability of anti-infective-coated catheters against multidrug-resistant bacteria. J AntimicrobChemother 62:746–750.
28. Fraenkel D, Rickard C, Thomas P, Faoagali J, George N, Ware R. 2006. A prospective, randomized trial of rifampicin-minocycline-coated and silver-platinum-carbon-impregnated central venous catheters. Crit Care Med 34:668–675.
29. Raad I, Darouiche R, Dupuis J, Abi-Said D, Gabrielli A, Hachem R, Wall M, Harris R, Jones J, Buzaid A, Robertson C, Shenaq S, Curling P, Burke T, Ericsson C. 1997. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial. The Texas Medical Center Catheter Study Group. Ann Intern Med 127:267–274.
30. Crump JA, Collignon PJ. 2000. Intravascular catheter-associated infections. Eur J ClinMicrobiol Infect Dis 19:1–8.
31. Schuerer DJ, Zack JE, Thomas J, Borecki IB, Sona CS, Schallom ME, Venker M, Nemeth JL, Ward MR, Verjan L, Warren DK, Fraser VJ, Mazuski JE, Boyle WA, Buchman TG, Coopersmith CM. 2007. Effect of chlorhexidine/silver sulfadiazine-impregnated central venous catheters in an intensive care unit with a low blood stream infection rate after implementation of an educational program: a before-after trial. Surg Infect (Larchmt) 8:445–454.
32. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, Fridkin SK. 2008. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infect Control HospEpidemiol 29:996–1011.
33. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, Herwaldt L, Pfaller M, Diekema D. 2003. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 37:1172–1177.

34. Chaiban G, Hanna H, Dvorak T, Raad I. 2005. A rapid method of impregnating endotracheal tubes and urinary catheters with gendine: a novel antiseptic agent. J AntimicrobChemother 55:51–56.
35. Saji M, Taguchi S, Uchiyama K, Osono E, Hayama N, Ohkuni H. 1995. Efficacy of gentian violet in the eradication of methicillin-resistant Staphylococcus aureus from skin lesions. J Hosp Infect 31:225–228.
36. Vazquez JA. 1999. Options for the management of mucosal candidiasis in patients with AIDS and HIV infection. Pharmacotherapy 19:76–87.
37. Noorani A, Rabey N, Walsh SR, Davies RJ. 2010. Systematic review and meta-analysis of preoperative antisepsis with chlorhexidine versus povidone-iodine in clean-contaminated surgery. Br J Surg 97:1614–1620.
38. Tanner J, Swarbrook S, Stuart J. 2008. Surgical hand antisepsis to reduce surgical site infection. Cochrane Database Syst Rev (1):CD004288.
39. El Arifeen S, Mullany LC, Shah R, Mannan I, Rahman SM, Talukder MR, Begum N, Al-Kabir A, Darmstadt GL, Santosham M, Black RE, Baqui AH. 2012. The effect of cord cleansing with chlorhexidine on neonatal mortality in rural Bangladesh: a community-based, cluster-randomised trial. Lancet 379:1022–1028.
40. Mullany LC, Biggar RJ. 2009. Vaginal and neonatal skin cleansing with chlorhexidine. Lancet 374:1873–1875.
41. Mullany LC, Darmstadt GL, Khatry SK, Katz J, LeClerq SC, Shrestha S, Adhikari R, Tielsch JM. 2006. Topical applications of chlorhexidine to the umbilical cord for prevention of omphalitis and neonatal mortality in southern Nepal: a community-based, cluster-randomised trial. Lancet 367:910–918.
42. Modak S, Sampath L, Miller HS, Millman I. 1992. Rapid inactivation of infectious pathogens by chlorhexidine-coated gloves. Infect Control HospEpidemiol 13:463–471.
43. Cheung HY, Wong MM, Cheung SH, Liang LY, Lam YW, Chiu SK. 2012. Differential actions of chlorhexidine on the cell wall of Bacillus subtilis and Escherichia coli. PLoS One 7:e36659.
44. Aljofan M, Sganga ML, Lo MK, Rootes CL, Porotto M, Meyer AG, Saubern S, Moscona A, Mungall BA. 2009. Antiviral activity of gliotoxin, gentian violet and brilliant green against Nipah and Hendra virus *in vitro*. Virol J 6:187.
45. Docampo R, Moreno SN, Gadelha FR, de Souza W, Cruz FS. 1988. Prevention of Chagas' disease resulting from blood transfusion by treatment of blood: toxicity and mode of action of gentian violet. Biomed Environ Sci 1:406–413.
46. Beier RC, Foley SL, Davidson MK, White DG, McDermott PF, Bodeis-Jones S, Zhao S, Andrews K, Crippen TL, Sheffield CL, Poole TL, Anderson RC, Nisbet DJ. 2014. Characterization of antibiotic and disinfectant susceptibility profiles among Pseudomonas aeruginosa veterinary isolates recovered during 1994–2003. J ApplMicrobiol 118:326–342.
47. Brooks SE, Walczak MA, Hameed R, Coonan P. 2002. Chlorhexidine resistance in antibiotic-resistant bacteria isolated from the surfaces of dispensers of soap containing chlorhexidine. Infect Control HospEpidemiol 23:692–695.
48. Gilbert P, McBain AJ. 2003. Potential impact of increased use of biocides in consumer products on prevalence of antibiotic resistance. ClinMicrobiol Rev 16:189–208.
49. Apisarnthanarak A, Yang Hsu L, Lim TP, Mundy LM. 2014. Increase in chlorhexidine minimal inhibitory concentration of Acinetobacterbaumannii clinical isolates after implementation of advanced source control. Infect Control HospEpidemiol 35:98–99.
50. Aggett PJ, Cooper LV, Ellis SH, McAinsh J. 1981. Percutaneous absorption of chlorhexidine in neonatal cord care. Arch Dis Child 56:878–880.
51. Lee A, Harlan R, Breaud AR, Speck K, Perl TM, Clarke W, Milstone AM. 2011. Blood concentrations of chlorhexidine in hospitalized children undergoing daily chlorhexidine bathing. Infect Control HospEpidemiol 32:395–397.
52. Nilsson G, Larsson L, Christensen KK, Christensen P, Dykes AK. 1989. Chlorhexidine for prevention of neonatal colonization with group B streptococci. V. Chlorhexidine concentrations in blood following vaginal washing during delivery. *Eur J ObstetGynecolReprodBiol* 31:221–226.
53. Chapman AK, Aucott SW, Gilmore MM, Advani S, Clarke W, Milstone AM. 2013. Absorption and tolerability of aqueous chlorhexidinegluconate used for skin antisepsis prior to catheter insertion in preterm neonates. J Perinatol 33:768–771.
54. Hachem R, Reitzel R, Borne A, Jiang Y, Tinkey P, Uthamanthil R, Chandra J, Ghannoum M, Raad I. 2009. Novel antiseptic urinary catheters for prevention of urinary tract infections: correlation of *in vivo* and *in vitro* test results. Antimicrob Agents Chemother 53:5145–5149.
55. Maley AM, Arbiser JL. 2013. Gentian violet: a 19th century drug re-emerges in the 21st century. ExpDermatol 22:775–780.

56. Wendel S. 1998. Transfusion-transmitted Chagas' disease. CurrOpinHematol 5:406–411.
57. Farid KJ, Kelly K, Roshin S. 2011. Gentian violet 1% solution in the treatment of wounds in the geriatric patient: a retrospective study. GeriatrNurs 32:85–95.

Cite this article:
Dr. Parija Jyothi Prakash. An Investigation Of The Biocompatibility And In Vitro Efficacy Of Antibiotic-Coated Central Catheters. ***ActaBiomedicaScientia***, 2014; 1(4): 200-210.